Pegcetacoplan, a C3 complement inhibitor that can potentially prevent both intravascular and extravascular hemolysis [32, 33], has been shown to be efficacious in treating PNH with clinically significant extravascular hemolysis, but there is a risk of severe breakthrough intravascular hemolysis [34, 35]. Here, C3 is linked to paroxysmal nocturnal hemoglobinuria.